ABUS
NASDAQ · Biotechnology
Arbutus Biopharma Corp
$4.55
+0.12 (+2.71%)
Financial Highlights (FY 2026)
Revenue
14.52M
Net Income
-34,529,592
Gross Margin
—
Profit Margin
-237.9%
Rev Growth
-28.8%
D/E Ratio
0.04
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 64.9% | 64.9% |
| Operating Margin | -271.0% | -243.9% | -11.9% | -12.7% |
| Profit Margin | -237.9% | -226.0% | -11.3% | -11.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 14.52M | 20.39M | 146.67M | 133.60M |
| Gross Profit | — | — | 95.21M | 86.72M |
| Operating Income | -39,340,742 | -49,728,466 | -17,469,791 | -16,985,358 |
| Net Income | -34,529,592 | -43,646,956 | -16,611,843 | -15,300,824 |
| Gross Margin | — | — | 64.9% | 64.9% |
| Operating Margin | -271.0% | -243.9% | -11.9% | -12.7% |
| Profit Margin | -237.9% | -226.0% | -11.3% | -11.5% |
| Rev Growth | -28.8% | -28.8% | -8.1% | +23.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 19.31M | 19.31M | 270.84M | 284.74M |
| Total Equity | 430.09M | 430.09M | 467.84M | 533.69M |
| D/E Ratio | 0.04 | 0.04 | 0.58 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -38,974,191 | -52,002,080 | -23,689,130 | -19,063,619 |
| Free Cash Flow | — | — | -19,958,595 | -16,903,048 |